Products
AI Benchmark
Desktop
Mobile
Monthly visits
<5K
Oct 2026
Public revenue
Undisclosed
No public revenue evidence yet
Entry price
$50/mo
Higher than 91% of peersNiche median $12.69/mo
Creators
Qinyah
No social account linked
Launched
12mo ago
2025-12-01 · Est.

Traffic

Last 12 months
Monthly visitsData through Oct 2026
Events1 marketing move

Marketing moves

Launches, search & content, referrals, promotions
  • Launched on Product HuntLaunch

    Chat with your data

    Dec 1, 2025 · 12mo agoLaunch page

Traffic sources

Oct 2026

Traffic breakdown

Channels

No data yet

Countries

No data yet

Search

Domain authority —Domain registered Unknown

No search keyword data for this website yet.

Traffic data: Vaneform

Pricing

Explorer
$50/mo
Pre-defined limits for storage, schema size, and request volumes
Enterprise
Unknown
Unlimited throughput · No enforced limits

Trial: None · 1 paid tier ($50) · Enterprise custom tier · Observed 2026-11-09 · Pricing page

Entry price $50/mo, Higher than 91% of peers; “Spreadsheets & Data Analysis AI” median is $12.69/mo.View pricing benchmark

Pages & changes

Tracked since 2025-12-01

Key pages

Weekly snapshots
revelate.entropy.sa/ Snapshot 2026-11-09

Changes

No pricing, plan, or positioning changes detected since tracking started.

Questions & evidence

How much does Revelate cost?
Explorer: $50/mo; Enterprise: Unknown. Observed 2026-11-09. Check the source for current billing terms, usage limits and taxes.Source
How much website traffic does Revelate get?
Vaneform estimates <5K website visits in 2026-10. Visits can include repeat visits; this estimate measures web traffic separately from paying customers or revenue.Source
What is Revelate and what platforms does it support?
Revelate is catalogued under Spreadsheets & Data Analysis AI: Talk with your data.. Supported platforms: Web.

Related products in this category

Data & Analytics / Spreadsheets & Data Analysis AI

These products share a catalog category. Compare customer tasks, features and deployment requirements before treating them as alternatives.